Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)
CNY 18.76
(-0.74%)
CNY 18.76
(-0.74%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 252.63 Million CNY | -95.06% |
| 2022 | 5.14 Billion CNY | 253.28% |
| 2021 | 1.72 Billion CNY | 199.79% |
| 2020 | 574.59 Million CNY | 808.08% |
| 2019 | 64.24 Million CNY | -25.1% |
| 2018 | 84.87 Million CNY | -0.07% |
| 2017 | 86.16 Million CNY | 20.68% |
| 2016 | 73.73 Million CNY | 68.37% |
| 2015 | 42.06 Million CNY | 62.35% |
| 2014 | 25.74 Million CNY | 194.2% |
| 2013 | 8.8 Million CNY | 386.1% |
| 2012 | 1.45 Million CNY | 353.88% |
| 2011 | 344.19 Thousand CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 18.72 Million CNY | 252.1% |
| 2024 Q2 | 7.27 Million CNY | 1.43% |
| 2024 Q3 | 10.35 Million CNY | -76.09% |
| 2023 Q3 | -17.9 Million CNY | -126.64% |
| 2023 Q4 | 113.06 Million CNY | 731.42% |
| 2023 FY | - CNY | -95.06% |
| 2023 Q1 | 58.31 Million CNY | -95.57% |
| 2023 Q2 | 67.22 Million CNY | 15.28% |
| 2022 Q4 | 1.31 Billion CNY | -3.05% |
| 2022 Q2 | 1.68 Billion CNY | -3.03% |
| 2022 Q1 | 1.73 Billion CNY | 259.31% |
| 2022 FY | - CNY | 253.28% |
| 2022 Q3 | 1.35 Billion CNY | -19.31% |
| 2021 Q1 | 443.91 Million CNY | 234.16% |
| 2021 Q3 | 521.56 Million CNY | 93.56% |
| 2021 Q2 | 269.45 Million CNY | -39.3% |
| 2021 Q4 | 483.07 Million CNY | -7.38% |
| 2021 FY | - CNY | 199.79% |
| 2020 Q2 | 239.6 Million CNY | 9759.23% |
| 2020 Q4 | 132.84 Million CNY | -29.65% |
| 2020 FY | - CNY | 808.08% |
| 2020 Q1 | 2.43 Million CNY | -62.06% |
| 2020 Q3 | 188.82 Million CNY | -21.19% |
| 2019 Q2 | 30.47 Million CNY | 77.2% |
| 2019 Q1 | 17.19 Million CNY | 10.3% |
| 2019 FY | - CNY | -25.1% |
| 2019 Q4 | 6.4 Million CNY | 238.85% |
| 2019 Q3 | 1.89 Million CNY | -93.8% |
| 2018 Q2 | 33.51 Million CNY | 71.66% |
| 2018 Q1 | 19.52 Million CNY | -4.47% |
| 2018 FY | - CNY | -0.07% |
| 2018 Q4 | 15.59 Million CNY | 82.35% |
| 2018 Q3 | 8.55 Million CNY | -74.49% |
| 2017 FY | - CNY | 20.68% |
| 2017 Q1 | 13.89 Million CNY | -19.02% |
| 2017 Q3 | 14.65 Million CNY | -48.28% |
| 2017 Q4 | 20.43 Million CNY | 39.47% |
| 2017 Q2 | 28.33 Million CNY | 103.84% |
| 2016 Q3 | 17.16 Million CNY | -5.35% |
| 2016 FY | - CNY | 68.37% |
| 2016 Q1 | 18.13 Million CNY | 76.53% |
| 2016 Q4 | 17.16 Million CNY | 0.0% |
| 2016 Q2 | 18.13 Million CNY | 0.0% |
| 2015 Q2 | 10.74 Million CNY | -0.0% |
| 2015 Q4 | 10.27 Million CNY | 0.0% |
| 2015 FY | - CNY | 62.35% |
| 2015 Q1 | 10.74 Million CNY | 49.25% |
| 2015 Q3 | 10.27 Million CNY | -4.37% |
| 2014 Q1 | 4.23 Million CNY | 37.09% |
| 2014 Q3 | 7.19 Million CNY | 70.08% |
| 2014 Q4 | 7.19 Million CNY | 0.0% |
| 2014 Q2 | 4.23 Million CNY | -0.0% |
| 2014 FY | - CNY | 194.2% |
| 2013 Q4 | 3.08 Million CNY | 0.0% |
| 2013 Q2 | 1.23 Million CNY | -0.0% |
| 2013 Q3 | 3.08 Million CNY | 150.71% |
| 2013 FY | - CNY | 386.1% |
| 2013 Q1 | 1.23 Million CNY | 0.0% |
| 2012 FY | - CNY | 353.88% |
| 2011 FY | - CNY | 0.0% |